Hearing News Watch

Hearing Health & Technology Matters today announces the winners of its third annual Hearing Technology Innovator Awards™. Through the annual awards program, HHTM honors technological innovation and achievement in the hearing industry. This year’s expanded program was the most competitive yet and received entries from some of the most innovative companies from around the world. “With the culmination of this

INDIANAPOLIS and BOSTON — Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. “We are honored to work with the talented team at Akouos who are breaking new ground

BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead

SAN DIEGO, CALIFORNIA — Not all cochlear implant cases present in a traditional manner, which calls for audiologists to seek a second opinion in more intricate and difficult cases. Complex Cochlear Implant Cases: Management and Troubleshooting offers both new and experienced cochlear implant audiologists the opportunity to tap into the knowledge and experience of skilled colleagues who have handled unique

A 15-year-old from Nebraska with cochlear implants and diagnosed at birth with hearing loss due to TMPRSS3 recently created a web resource devoted to TMPRSS3, the fifth most common gene causally associated with deafness.  For her efforts, Lily received the Girl Scout Gold Award, the highest honor a Girl Scout can receive. Her website, https://www.tmprss3.org, aims to help people with

SAN DIEGO, CALIFORNIA — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss demonstrated no clinically meaningful improvement for patients from baseline across multiple speech-in-noise (SIN) hearing tests. These results are in

WASHINGTON, D.C. — Today, the U.S. Food and Drug Administration (FDA) sent a letter to state officials offering clarifications about the Final Rule on OTC Hearing Aids, following requests by several professional organizations seeking to better understand the distinction between ‘Prescription’ and ‘OTC’ hearing aid categories. In part, the letter states, “We have received questions about some implications of these actions,

STAMFORD, CT and DENVER, CO – Synchrony (NYSE: SYF), a leading consumer financing company, today announced the availability of Allegro Credit, a point of sale consumer financing solution for the hearing industry, on Sycle’s practice management platform. With the new integration, audiology providers can more quickly and easily deploy a comprehensive set of financing options – from a healthcare credit card

It was another successful EUHA for RAYOVAC, a brand of battery manufacturer Energizer Holdings*, as it showcased its latest technology to hundreds of new delegates at the hearing industry’s largest annual event in Hannover, Germany.The company began shipping RAYOVAC® Sound Fusion™ Technology to the market this summer, in sizes 10, 13 and 312, with up to two-and-a-half days more battery

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show